<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01408550</url>
  </required_header>
  <id_info>
    <org_study_id>NPB-01-06/C-01</org_study_id>
    <nct_id>NCT01408550</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids</brief_title>
  <official_title>NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nihon Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nihon Pharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national
      diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the
      exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five
      consecutive days or Placebo(physiological saline). Subsequently, efficacy of NPB-01 for
      therapy of bullous pemphigoid will be evaluated the score using pemphigus disease area index
      (PDAI) and pemphigoid activity score involving skin lesion area and Number of new blisters.

      As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse
      events by 57 days after the start of the study treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The score using Pemphigus Disease Area Index (PDAI)</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pemphigoid Activity Score</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-BP180 antibody titers</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Steroid dose</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <arm_group>
    <arm_group_label>NPB-01</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator: 1 Intravenous immunoglobulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator: 2 Physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NPB-01</intervention_name>
    <description>Intravenous immunoglobulin</description>
    <arm_group_label>NPB-01</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Physiological saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with corticosteroids over 0.4mg/kg/day(Prednisolone) at informed consent.

          2. Patients with continued treatment for bullous pemphigoid without add or change the
             treatment after informed consent.

          3. Patients who the score using Pemphigus Disease Area Index(PDAI) is score10 and more
             before study medication received.

          4. Patients who the score using Pemphigus Disease Area Index(PDAI) is not improve before
             study medication received.

          5. Patients with twenty years old at informed consent.

          6. Patients with hospitalization during five consecutive days of study medication and
             seven consecutive days after administration of study medication .

        Exclusion Criteria:

          1. Patients treated with plasmapheresis at 28 days before informed consent.

          2. Patients treated with corticosteroids pulse therapy(methylprednisolone over 0.5g/day)
             at 14 days before informed consent.

          3. Patients treated with intravenous immunoglobulin at 56 days before informed consent.

          4. Patients who receive or adjust in increments immunosuppressants at 14 days before
             informed consent.

          5. Patients with malignancy or a history of this disease.

          6. Patients with history of shock for NPB-01.

          7. Patients with history of hypersensitivity for NPB-01.

          8. Patients with IgA deficiency.

          9. Patients with impaired liver function.

         10. Patients with impaired renal function.

         11. Patients with cerebro- or cardiovascular disorders.

         12. Patients with high risk of thromboembolism.

         13. Patients with hemolytic/hemorrhagic anemia.

         14. Patients with decreased cardiac function.

         15. Patients with decreased platelet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>August 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2011</study_first_posted>
  <last_update_submitted>October 15, 2013</last_update_submitted>
  <last_update_submitted_qc>October 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <name_title>Nihon Pharmaceutical Co., Ltd</name_title>
    <organization>Clinical Development Department</organization>
  </responsible_party>
  <keyword>IVIG in pemphigoid</keyword>
  <keyword>Patients with bullous pemphigoid unresponsive to corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

